Bradford A. Perez

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Luis Paz‐Ares, Alexander I. Spira, David Raben et al. · Annals of Oncology · 2020 · 217 citations · Full text

Pacific Trial, Medicine, Immunology +6

TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures

Ricardo A. Chaurio, Carmen M. Anadon, Tara Lee Costich et al. · Immunity · 2022 · 162 citations · Full text

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells

Carmen M. Anadon, Xiaoqing Yu, Kay Hänggi et al. · Cancer Cell · 2022 · 157 citations · Full text

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj et al. · The Lancet · 2022 · 126 citations · Full text

Open Label, Radiation Therapy, Medicine +6

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases

Kamran A. Ahmed, Sungjune Kim, John A. Arrington et al. · Journal of Neuro-Oncology · 2017 · 122 citations

Radiation Therapy, Pd-1/pd-l1 Axis, Medicine +7